ReviewFrontiers in immunology2020
Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.Frontiers in immunology · 2021Trial
- Dynamic Metabolic Profiling and Diagnostic Biomarkers of Acute Graft-Versus-Host Disease Based on Metabolomics.Biomedical chromatography : BMC · 2026Article
- Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- Metabolomic Signatures of Relapse and Survival in AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.Hematology reports · 2026Article
- Percentage of CD56Annals of hematology · 2026Article
- DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.Blood reviews · 2025Review
- Immune Monitoring after Cell Therapy and Hematopoietic Cell Transplantation: Guidelines by the ISCT Stem Cell Engineering Committee.Cytotherapy · 2025Review
- A donor PD-1Signal transduction and targeted therapy · 2025Article
- Age-enhanced MAGIC algorithm predicts mortality in pediatric aGVHD: a multicenter study.Frontiers in immunology · 2025Article
- The Role of Epigenetic Modifications in Enhancing Bone Marrow Transplantation Efficacy in Cancer.Advances in experimental medicine and biology · 2025Review
- Review
- Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.Bone marrow transplantation · 2024Article
- Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology.Science advances · 2023Article
- Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.Frontiers in medicine · 2023Article
- HighCancers · 2022Article
- Prospective external validation of biomarkers to predict acute graft-versus-host disease severity.Blood advances · 2022Article
- GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-established curative treatment for various malignant hematological diseases. However, its clinical success is substantially limited by major complications including graft-vs.-host disease (GVHD) and relapse of the underlying disease. Although these complications are known to lead to significant morbidity and mortality, standardized pathways for risk stratification of patients undergoing allo-HSCT are lacking. Recent advances in the development of diagnostic and prognostic tools have allowed the identification of biomarkers in order to predict outcome after allo-HSCT. This review will provide a summary of clinically relevant biomarkers that have been studied to predict the development of acute GVHD, the responsiveness of affected patients to immunosuppressive treatment and the risk of non-relapse mortality. Furthermore, biomarkers associated with increased risk of relapse and subsequent mortality will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.